A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V

Inclusion Criteria: * Male or female patient with a molecular-genetically confirmed diagnosis of XP-C or XP-V; * Aged 18-75 years. Exclusion Criteria: * Known allergy to afamelanotide or the polymer contained in the implant; * Presence of severe hepatic disease or hepatic impairment; * Renal impairment; * Any other medical condition which may interfere with the study protocol; * Existing melanoma; * Female who is pregnant or lactating; * Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures; * Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures; * Use of any other prior and concomitant therapy which may interfere with the objective of the study; * Participation in a clinical trial for an investigational agent.